Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.

Gene therapy·2015
Same author

Growth-suppressive activities of serine protease inhibitors, FOY-305, ONO-3403 and FO-349 toward human carcinoma cells.

Oncology reports·2011
Same author

Screening of peptides which suppress the proliferation of transformed cells.

International journal of oncology·2011
Same author

Enhancement of anti-proliferative activities of 5-FU, HCFU, SN-38, THP and ACNU by a serine protease inhibitor, FOY-305.

International journal of oncology·2011
Same author

Enhancement of chemosensitivity toward peplomycin by calpastatin-stabilized NF-kappaB p65 in esophageal carcinoma cells: possible involvement of Fas/Fas-L synergism.

Apoptosis : an international journal on programmed cell death·2006
Same author

Cathepsin L activity and its inhibitor in human otitis media.

The Journal of otolaryngology·2002

Related Experiment Video

Updated: Jun 1, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Ras inhibitors.

T Hiwasa

    Oncology Reports
    |May 20, 2011
    PubMed
    Summary

    Researchers are exploring various compounds and genetic probes to inhibit ras-oncogene activity. Some of these Ras inhibitors show potential as novel cancer therapeutics.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Biochemistry

    Background:

    • Ras-oncogenes play a critical role in cancer development.
    • Targeting Ras signaling pathways is a key strategy in cancer therapy.
    • Numerous molecular entities have been investigated for their ability to inhibit Ras activity.

    Purpose of the Study:

    • To review and categorize known inhibitors of ras-oncogene activity.
    • To highlight the diverse mechanisms of action employed by these inhibitors.
    • To assess the potential of these inhibitors as cancer therapeutic agents.

    Main Methods:

    • Literature review of proteins and compounds affecting Ras activity.
    • Categorization of inhibitors based on their mechanism of action (e.g., blocking activation, downstream effects, genetic probes).

    Related Experiment Videos

    Last Updated: Jun 1, 2026

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
    08:21

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

    Published on: October 26, 2020

  • Analysis of Ras inhibitors including anti-Ras antibodies, dominant-negative mutants, and antisense oligonucleotides.

    • Main Results:

    • A wide array of Ras inhibitors have been identified, including antibodies, small molecules, genetic probes (oligonucleotides, ribozymes), and dominant-negative mutants.
    • Inhibitors target various stages of Ras protein function, from activation and processing to downstream signaling.
    • The precise mechanisms of action for some identified Ras inhibitors are yet to be fully elucidated.

    Conclusions:

    • A diverse arsenal of molecules and strategies exists to suppress ras-oncogene activity.
    • Several Ras inhibitors demonstrate potential for development into effective cancer therapeutics.
    • Further research is needed to fully understand the mechanisms of action for all identified inhibitors and optimize their therapeutic application.